It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

"Anti-vaccine rhetoric is a threat to global health," said biomedical scientist Andrea C. Love, PhD, emphasizing how ...

A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...

A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Although reports of vision problems with weight loss drugs are still rare, researchers say there is cause for concern because ...

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...

As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...